ZYN002

Phase 3Small molecule

HHarmony Biosciences Management, Inc.

ZYN002 is one of 38 small molecule programs targeting 22q11.2 deletion syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

22q11.2 Deletion SyndromeActive, not recruiting

Fragile X SyndromeActive, not recruiting

22q11.2 Deletion SyndromePhase 2

Active, not recruiting

Fragile X SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

46 competitors in Fragile X Syndrome

#DrugCompanyPhaseTrials

Epidiolex

Daliresp

Namenda

Glucophage

4 5

Lioresal

Novartis

Approved

—6

Rilutek

AAzurity Pharmaceuticals

Approved

1 7

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 8

Minocin

TTriax

Approved

1 9

Lithobid

SSolvay Pharmaceuticals

Approved

—10

Clinoril

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

22q11.2 deletion syndrome1 trial

Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)

Completed·HHarmony Biosciences Management, Inc.·Phase 2·NCT05149898·20 enrolled

Fragile X Syndrome1 trial

Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome

Completed·ZZynerba Pharmaceuticals, Inc.·Phase 3·NCT04977986·215 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ZYN002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZYN002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZYN002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Harmony Biosciences Management, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHarmony Biosciences Management, Inc.

ZYN002

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

22q11.2 deletion syndrome1 trial

Fragile X Syndrome1 trial

References

Drug Info

Quick Facts

Related News